The Safety and Efficacy of RIC on Adult Moyamoya Disease

• Status: Completed
• Trial end date: 2021-02-02
• Target enrollment: 0
• Participant gender: All

Summary

There are a series of symptoms such as ischemic stroke、transient ischemic attack 、hemorrhagic stroke、headache 、seizure and so on in moyamoya disease( MMD) patients .Nowadays, revascularization is the only effective way for ischemic MMD and there is no effective conservative treatment for MMD. This study was to explore the safety and efficacy of remote ischemic conditioning(RIC ) on adult MMD patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Capital Medical University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Age: 18-60 years

• All of the patients underwent digital subtraction angiography (DSA) and met the current diagnostic criteria recommended by the Research Committee on MMD of the Ministry of Health and Welfare of Japan in 2012.

• mRs≤3

• Informed consent obtained from patient or acceptable patient's surrogate.

Exclusion Criteria:

• Patients with acute ischemic or hemorrhagic stroke within 3 months.

• Severe hepatic or renal dysfunction.

• Severe hemostatic disorder or severe coagulation dysfunction.

• Severe cardiac diseases.

• Patients with severe existing neurological or psychiatric disease

• Patients with moyamoya syndrome caused by autoimmune disease, Down syndrome , neurofibromatosis, leptospiral infection, or previous skull-base radiation therapy.

• Patients have been done or plan to accept revascularization surgery.